A New PET Labeled Maltodextrin for Diagnosis of Bacterial Infections
用于诊断细菌感染的新型 PET 标记麦芽糖糊精
基本信息
- 批准号:9141215
- 负责人:
- 金额:$ 22.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-07-01 至 2017-12-31
- 项目状态:已结题
- 来源:
- 关键词:Animal ModelAntibioticsBacteriaBacterial InfectionsBusinessesChemical StructureClinicalContrast MediaDataDebridementDegenerative polyarthritisDetectionDevelopmentDiagnosisEarly DiagnosisElderlyEvaluationExcisionFamilyFluorineGenerationsGlucoseGuidelinesHealth Care CostsHip region structureImageImplantImplantation procedureInfectionKneeLabelLaboratoriesLeadLife ExpectancyMaltoseMammalian CellMarketingMedicalMedical DeviceMembraneMicrobial BiofilmsModelingMorbidity - disease rateMuscleMyocardiumOrganOrthopedicsPainPathway interactionsPatientsPhase I Clinical TrialsPositronPositron-Emission TomographyPreparationProceduresPropertyReplacement ArthroplastyRodent ModelSafetySavingsSensitivity and SpecificitySourceSpecificityStagingTechnologyTestingTimeTissuesToxic effectToxicologyVendorbasebonedesignfluorescence imaginghip replacement arthroplastyimaging agentimaging modalityimaging probeimplantable devicein vivojoint functionknee replacement arthroplastymaltodextrinmedical implantmortalitypublic health relevanceresearch studysingle photon emission computed tomographytargeted imagingtreatment strategy
项目摘要
DESCRIPTION (provided by applicant): We present a new family of contrast agents, based on targeting the maltodextrin transporter termed maltodextrin based imaging probes (MDPs), which are designed to image infections associated with implanted medical devices by fluorescent imaging. The chemical structure of an MDP is composed of maltodextrins conjugated to the positron emitting radioelement fluorine-18. MDPs have the potential to offer significant advantages over existing methods for imaging bacteria, such as FDG, as a result of their high specificity and sensitivity for bacteria. MDPs target the maltodextrin transport pathway
and are internalized as a major source of glucose by bacteria. MDPs can therefore deliver millimolar concentrations of imaging probes into bacteria, making it possible to image low numbers of bacteria. MDPs also have high specificity for bacteria because mammalian cells do not express the maltodextrin transporter and thus cannot internalize contrast agents conjugated to maltose. Finally, MDPs are composed of glucose oligomers, which are hydrophilic and membrane impermeable. MDPs are therefore efficiently cleared from un-infected tissues in vivo, leading to low background in organs such as the heart and muscle, which should lead to high sensitivity imaging of implanted device infections. These unique properties allow MDPs to accurately image small numbers of bacteria in vivo. MDPs thus have the unique properties allow MDPs to accurately image small numbers of bacteria in vivo. MDPs thus have the potential to detect implant device infections at an early stage and enable their treatment before they are challenging to eradicate.
描述(由申请人提供):我们提出了一种新的造影剂系列,其基于靶向麦芽糊精转运蛋白,称为基于麦芽糊精的成像探针(MDP),旨在通过荧光成像对与植入式医疗器械相关的感染进行成像。MDP的化学结构由与正电子发射放射性元素氟-18共轭的麦芽糖糊精组成。MDP有可能提供显着的优势,超过现有的细菌成像方法,如FDG,由于其对细菌的高特异性和灵敏度。MDPs靶向麦芽糖糊精转运途径
并被细菌内化为葡萄糖的主要来源。因此,MDP可以将毫摩尔浓度的成像探针输送到细菌中,从而可以对少量细菌进行成像。MDP对细菌也具有高特异性,因为哺乳动物细胞不表达麦芽糖糊精转运蛋白,因此不能内化与麦芽糖缀合的造影剂。最后,MDP由葡萄糖低聚物组成,其是亲水性和膜不可渗透的。因此,MDP在体内从未感染的组织中有效清除,导致器官如心脏和肌肉中的低背景,这应该导致植入装置感染的高灵敏度成像。这些独特的特性使MDP能够准确地对体内少量细菌进行成像。因此,MDP具有独特的特性,允许MDP在体内准确地对少量细菌进行成像。因此,MDP有可能在早期阶段检测植入器械感染,并在难以根除之前进行治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael L Wach其他文献
Michael L Wach的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
DYNBIOTICS - Understanding the dynamics of antibiotics transport in individual bacteria
DYNBIOTICS - 了解抗生素在单个细菌中转运的动态
- 批准号:
EP/Y023528/1 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
Research Grant
Engineering Streptomyces bacteria for the sustainable manufacture of antibiotics
工程化链霉菌用于抗生素的可持续生产
- 批准号:
BB/Y007611/1 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
Research Grant
Hitting bacteria with a Bam: Lectin-Like Antimicrobials as New Antibiotics
用 Bam 击中细菌:凝集素类抗菌剂作为新型抗生素
- 批准号:
DP230102150 - 财政年份:2023
- 资助金额:
$ 22.5万 - 项目类别:
Discovery Projects
Systematic identification of synthetic interactions in bacteria towards the next-generation of antibiotics
系统鉴定细菌与下一代抗生素的合成相互作用
- 批准号:
468567 - 财政年份:2022
- 资助金额:
$ 22.5万 - 项目类别:
Operating Grants
“L-form” bacteria: basic science, antibiotics, evolution and biotechnology
L 型细菌:基础科学、抗生素、进化和生物技术
- 批准号:
FL210100071 - 财政年份:2022
- 资助金额:
$ 22.5万 - 项目类别:
Australian Laureate Fellowships
Repurposing Gram-positive Antibiotics for Gram-Negative Bacteria using Antibiotic Adjuvants
使用抗生素佐剂重新利用革兰氏阳性抗生素治疗革兰氏阴性菌
- 批准号:
10708102 - 财政年份:2022
- 资助金额:
$ 22.5万 - 项目类别:
Repurposing Gram-positive Antibiotics for Gram-Negative Bacteria using Antibiotic Adjuvants
使用抗生素佐剂重新利用革兰氏阳性抗生素治疗革兰氏阴性菌
- 批准号:
10587015 - 财政年份:2022
- 资助金额:
$ 22.5万 - 项目类别:
Isolation, identification and characterization of potentially novel antibiotics from rhizospheric bacteria without detectable in vitro resistance
从根际细菌中分离、鉴定和表征潜在的新型抗生素,且体外未检测到耐药性
- 批准号:
10581945 - 财政年份:2021
- 资助金额:
$ 22.5万 - 项目类别:
Developing novel antibiotics from natural products against resistant bacteria
从天然产物中开发针对耐药细菌的新型抗生素
- 批准号:
2599490 - 财政年份:2021
- 资助金额:
$ 22.5万 - 项目类别:
Studentship
Isolation, identification and characterization of potentially novel antibiotics from rhizospheric bacteria without detectable in vitro resistance
从根际细菌中分离、鉴定和表征潜在的新型抗生素,且体外未检测到耐药性
- 批准号:
10358855 - 财政年份:2021
- 资助金额:
$ 22.5万 - 项目类别: